Strides Pharma Science Crescita futura

Future criteri di controllo 4/6

Strides Pharma Science prevede che gli utili e i ricavi cresceranno rispettivamente di 45.6% e 11% all'anno. Si prevede che l'EPS crescerà di 45.9% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 19.8% in 3 anni.

Informazioni chiave

45.6%

Tasso di crescita degli utili

45.9%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	17.8%
Tasso di crescita dei ricavi	11.0%
Rendimento futuro del capitale proprio	19.8%
Copertura analitica	Low
Ultimo aggiornamento	25 Oct 2024

Aggiornamenti recenti sulla crescita futura

Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Aug 02

Recent updates

Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors

Nov 01

Why Investors Shouldn't Be Surprised By Strides Pharma Science Limited's (NSE:STAR) 27% Share Price Surge

Oct 21

After Leaping 29% Strides Pharma Science Limited (NSE:STAR) Shares Are Not Flying Under The Radar

Aug 14

Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)

Apr 04

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Feb 29

Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story

Dec 23

We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt

Sep 26

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Jun 08

Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Aug 02

Is Strides Pharma Science (NSE:STAR) A Risky Investment?

Jun 25

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Dec 21

Strides Pharma Science (NSE:STAR) Has Announced That It Will Be Increasing Its Dividend To ₹2.50

Jul 28

Estimating The Fair Value Of Strides Pharma Science Limited (NSE:STAR)

Apr 13

Should Strides Pharma Science Limited (NSE:STAR) Be Part Of Your Dividend Portfolio?

Mar 04

These 4 Measures Indicate That Strides Pharma Science (NSE:STAR) Is Using Debt Extensively

Feb 15

Can Mixed Fundamentals Have A Negative Impact on Strides Pharma Science Limited (NSE:STAR) Current Share Price Momentum?

Jan 26

The Strides Pharma Science (NSE:STAR) Share Price Is Up 140% And Shareholders Are Boasting About It

Jan 11

Previsioni di crescita degli utili e dei ricavi

NSEI:STAR - Stime future degli analisti e dati finanziari passati (INR Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
3/31/2027	58,162	7,413	9,390	9,390	3
3/31/2026	51,466	5,688	8,671	8,810	4
3/31/2025	46,565	4,209	6,953	6,953	3
9/30/2024	44,103	1,771	6,344	8,172	N/A
6/30/2024	42,086	-475	N/A	N/A	N/A
3/31/2024	40,511	-1,248	5,829	7,011	N/A
12/31/2023	39,535	-1,525	N/A	N/A	N/A
9/30/2023	37,806	-2,280	3,043	3,903	N/A
6/30/2023	36,783	-924	N/A	N/A	N/A
3/31/2023	36,884	-2,212	-505	444	N/A
12/31/2022	35,680	-1,824	N/A	N/A	N/A
9/30/2022	34,976	-2,241	-2,101	-1,144	N/A
6/30/2022	33,220	-3,909	N/A	N/A	N/A
3/31/2022	30,703	-4,602	-4,012	-2,578	N/A
12/31/2021	31,127	-4,425	N/A	N/A	N/A
9/30/2021	31,504	-2,830	-1,188	1,572	N/A
6/30/2021	32,224	-543	N/A	N/A	N/A
3/31/2021	33,159	2,545	1,840	4,814	N/A
12/31/2020	30,260	28	N/A	N/A	N/A
9/30/2020	29,264	589	970	2,699	N/A
6/30/2020	28,480	1,266	N/A	N/A	N/A
3/31/2020	27,520	492	548	2,048	N/A
12/31/2019	35,828	2,859	N/A	N/A	N/A
9/30/2019	34,203	2,169	-1,519	1,896	N/A
6/30/2019	32,248	745	N/A	N/A	N/A
3/31/2019	21,784	840	-2,690	601	N/A
12/31/2018	28,547	-93	N/A	N/A	N/A
9/30/2018	28,090	139	N/A	N/A	N/A
6/30/2018	28,451	415	N/A	N/A	N/A
3/31/2018	28,451	544	N/A	1,871	N/A
12/31/2017	35,810	1,050	N/A	N/A	N/A
9/30/2017	36,593	1,124	N/A	N/A	N/A
6/30/2017	35,357	1,712	N/A	N/A	N/A
3/31/2017	27,554	2,335	N/A	2,881	N/A
12/31/2016	37,237	2,840	N/A	N/A	N/A
9/30/2016	36,573	2,410	N/A	N/A	N/A
6/30/2016	34,189	2,168	N/A	N/A	N/A
3/31/2016	28,622	1,317	N/A	732	N/A
12/31/2015	24,901	1,152	N/A	N/A	N/A
9/30/2015	12,962	860	N/A	N/A	N/A
6/30/2015	12,105	244	N/A	N/A	N/A
3/31/2015	11,958	16	N/A	834	N/A
3/31/2014	10,728	-1,867	N/A	-2,173	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di STAR ( 45.6% all'anno) è superiore al tasso di risparmio ( 6.7% ).

Guadagni vs Mercato: Si prevede che gli utili di STAR ( 45.6% all'anno) cresceranno più rapidamente del mercato Indian ( 18.1% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di STAR cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di STAR ( 11% all'anno) crescerà più rapidamente del mercato Indian ( 10.5% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di STAR ( 11% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di STAR sarà basso tra 3 anni ( 19.8 %).

Strides Pharma Science Crescita futura

Future criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target increased by 20% to ₹994

Forecast breakeven date pushed back to 2025

Price target increased by 10% to ₹730

Price target increased by 10% to ₹530

Price target decreased by 7.2% to ₹462

Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Recent updates

Strides Pharma Science Limited Announces Appointment of Dr. C Muthulingam as Executive Vice President - Research & Development

Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors

Second quarter 2025 earnings released: EPS: ₹10.14 (vs ₹14.54 loss in 2Q 2024)

Why Investors Shouldn't Be Surprised By Strides Pharma Science Limited's (NSE:STAR) 27% Share Price Surge

Strides Pharma Science Limited to Report Q2, 2025 Results on Oct 24, 2024

Upcoming dividend of ₹2.50 per share

Strides Pharma Science Limited, Annual General Meeting, Sep 25, 2024

After Leaping 29% Strides Pharma Science Limited (NSE:STAR) Shares Are Not Flying Under The Radar

Strides Pharma Science Limited Announces Completion of Tenure of S Sridhar as Independent Director

First quarter 2025 earnings released: EPS: ₹7.64 (vs ₹0.79 loss in 1Q 2024)

Strides Pharma Science Limited to Report Q1, 2025 Results on Jul 29, 2024

Insufficient new directors

New minor risk - Dividend sustainability

Strides Pharma Science Limited Announces Chief Financial Officer Changes, Effective June 1, 2024

Price target increased by 20% to ₹994

Forecast breakeven date pushed back to 2025

Strides Pharma Science Limited to Report Q4, 2024 Results on May 22, 2024

Strides Pharma Science Limited Approves Appointment of Ameet P Hariani as Independent Director

Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Price target increased by 10% to ₹730

Third quarter 2024 earnings released: ₹0.49 loss per share (vs ₹8.86 loss in 3Q 2023)

Strides Pharma Science Limited to Report Q3, 2024 Results on Jan 30, 2024

Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story

Strides Pharma Global Pte. Limited Receives USFDA Approval for Generic Suprep®? Bowel Prep Kit

Now 21% undervalued

Strides Pharma Science Limited Announces Change in Management

Second quarter 2024 earnings released: ₹14.54 loss per share (vs ₹0.47 profit in 2Q 2023)

Strides Pharma Science Limited to Report Q2, 2024 Results on Oct 30, 2023

New major risk - Revenue and earnings growth

We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt

Strides Pharma Global Pte. Limited Receives Tentative United States Food & Drug Administration Approval for Dolutegravir Tablets

Strides Pharma Science Limited Announces Resignation of Ankit Gupta as Vice President and Head of Corporate Development and Strategy

Price target increased by 10% to ₹530

Upcoming dividend of ₹1.50 per share at 0.3% yield

Strides Pharma Science Limited to Report Q1, 2024 Results on Aug 02, 2023

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Strides Pharma Science Limited Recommends Dividend for Financial Year Ended March 31, 2023

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Strides Pharma Science Limited to Report Q4, 2023 Results on May 25, 2023

Price target decreased by 7.2% to ₹462

Third quarter 2023 earnings released: ₹8.86 loss per share (vs ₹13.55 loss in 3Q 2022)

Strides Pharma Science Limited to Report Q3, 2023 Results on Jan 24, 2023

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹2.54 (vs ₹18.12 loss in 2Q 2022)

Insufficient new directors

Strides Pharma Science Limited Announces Resignation of Director

Strides Pharma Science Limited to Report Q2, 2023 Results on Nov 14, 2022

Strides Pharma Science Limited, Annual General Meeting, Sep 09, 2022

Strides Pharma Science Limited, Annual General Meeting, Sep 09, 2022

Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

First quarter 2023 earnings released: ₹15.13 loss per share (vs ₹22.88 loss in 1Q 2022)

Strides Pharma Science Limited to Report Q1, 2023 Results on Jul 29, 2022

Is Strides Pharma Science (NSE:STAR) A Risky Investment?

Stelis Biopharma Limited and Strides Pharma Science Limited Receive the European Union Goods Manufacturing Practices (EU-GMP) Compliance Certificate

Now 20% undervalued after recent price drop

Strides Receives USFDA Approval for Ibuprofen Oral Suspension

Full year 2022 earnings: EPS misses analyst expectations

Strides Pharma Science Limited to Report Q4, 2022 Results on May 24, 2022

Price target decreased to ₹463

Insufficient new directors

Insufficient new directors

Strides Pharma Science Limited Announces Executive Changes

Founder & Non-Executive Chairman recently bought ₹50m worth of stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Strides Pharma Science Limited announced that it expects to receive INR 485 million in funding from Karuna Business Solutions LLP

Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?

Price target decreased to ₹735

Second quarter 2022 earnings released: ₹18.12 loss per share (vs ₹7.38 profit in 2Q 2021)